Skip to main content
Probi logo

Probi — Investor Relations & Filings

Ticker · PROB ISIN · SE0001280355 LEI · 5493004CJOCT273MU397 ST Manufacturing
Open in API
Filings indexed 410 across all filing types
Latest filing 2012-08-16 Interim / Quarterly Rep…
Country SE Sweden
Listing ST PROB

About Probi

https://www.probi.com/

Probi is a global biotics company specializing in the research, development, and manufacturing of clinically documented probiotic strains. The company provides biotic solutions for dietary supplements and functional foods, targeting specific health needs across various life stages. Its portfolio addresses key areas such as digestive, immune, mental, and metabolic health, alongside specialized formulations for women, children, and healthy aging. Probi's offerings are founded on extensive scientific research and clinical studies to ensure proven efficacy in supporting human health.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2012
Interim / Quarterly Report Classification · 1% confidence The document is a 'Delårsrapport' (Interim Report) for Probi AB covering the period 2012-01-01 to 2012-06-30. It contains comprehensive financial statements, including income statements, cash flow analysis, segment reporting, and management commentary on business performance. It is not a mere announcement (RPA) as it contains substantive financial data and analysis for the six-month period. H2 2012
2012-08-16 Swedish
Probis indiska IBS-studie publicerad i World Journal of Gastroenterology
Regulatory Filings Classification · 1% confidence The document is a press release (PRESSMEDDELANDE) announcing that a study regarding the company's product (*Lactobacillus plantarum* 299v) for Irritable Bowel Syndrome (IBS) has been published in the World Journal of Gastroenterology. It details the study's positive results and mentions that this documentation will support an application to EFSA for a health claim. This is not a formal regulatory filing like a 10-K or IR, nor is it a general earnings release (ER). It is a specific announcement about research findings and their implications, which fits best under the general category for regulatory announcements or specific research/legal updates. Since it is an announcement of published research that supports future regulatory claims, and it doesn't fit the specific definitions for LTR (Legal Proceedings) or ER (Earnings Release), it falls under the general Regulatory Filings (RNS) category as a significant corporate/research update released to the public market, or potentially a general announcement (RPA) if it were announcing the *release* of a report, but here it announces the *publication* of a third-party study. Given the context of corporate communication about research validation, RNS is the most appropriate general regulatory/public disclosure category for this type of news.
2012-08-16 Swedish
Probi och Alvogen lanserar Probi Digestis® och Probi Defendum® i Taiwan
Regulatory Filings Classification · 1% confidence The document is a press release (PRESSMEDDELANDE) announcing a new distribution agreement between Probi and Alvogen for launching Probi's products in Taiwan. This announcement details a business partnership and commercial strategy, which does not fit neatly into the specific financial reporting categories (like 10-K, ER, IR) or corporate governance filings (like DEF 14A, DIRS). It is a general business update concerning market expansion and distribution, which is best categorized as a general regulatory announcement or miscellaneous filing that doesn't fit elsewhere. Given the options, 'Regulatory Filings' (RNS) serves as the most appropriate fallback for significant, non-standardized corporate news releases that are not explicitly defined elsewhere.
2012-07-03 Swedish
Probi to launch gut and immune health products in Taiwan with Alvogen
Regulatory Filings Classification · 1% confidence The document is a press release announcing a distribution agreement between Probi and Alvogen for launching Probi's products in Taiwan. It details the products, the partner, and the expected launch timeline (Q1 2013). This type of announcement, which is not a formal regulatory filing like a 10-K, an earnings release (ER), or a specific capital event, falls best under the general category for regulatory announcements that don't fit elsewhere, which is Regulatory Filings (RNS). It is a general corporate announcement regarding business development, submitted for disclosure, but it is not a specific financial report, management change, or transaction report defined by the other codes. Given the nature of the announcement (a business partnership/distribution deal), RNS is the most appropriate fallback.
2012-07-03 English
Major Shareholding Notification 2012
Major Shareholding Notification Classification · 1% confidence The document explicitly details changes in shareholding percentages and quantities for an 'Issuer' (PROBI Aktiebolag) by a 'Holder' (Consepio). Key phrases like 'Reason for major shareholding notification Sell', 'Percentage', 'Shares', and the structure of reporting holdings before and after a transaction are characteristic of notifications required when an investor crosses specific ownership thresholds. This directly matches the definition for Major Shareholding Notification (MRQ). The document is not a full annual report (10-K), an earnings release (ER), or a proxy statement (DEF 14A/PSI).
2012-06-21 English
Probi och Vifor Pharma lanserar Probi Digestis® och Probi Defendum® i Schweiz
Regulatory Filings Classification · 1% confidence The document is a 'PRESSMEDDELANDE' (Press Release) announcing a new commercial agreement between Probi and Vifor Pharma for launching probiotic products in Switzerland. It details the partnership, product names, and expected launch timeline (Q4 2012/Q1 2013). This type of announcement, which is not a formal financial report (like 10-K or IR), nor a specific insider trade (DIRS), dividend notice (DIV), or capital change (CAP), falls best under the general category for regulatory announcements or miscellaneous corporate news that doesn't fit elsewhere. Given the options, 'Regulatory Filings' (RNS) serves as the appropriate fallback for general corporate news releases that are mandatory disclosures but lack a more specific category, although 'LTR' (Legal Proceedings Report) or 'TAR' (M&A Activity) are clearly incorrect. Since it is a general corporate announcement, RNS is the most suitable classification.
2012-05-08 Swedish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.